Differential upregulation of human 2′5′OAS genes on systemic sclerosis: Detection of increased basal levels of OASL and OAS2 genes through a qPCR based assay

References

• Kristiansen, H., H. H. Gad, S. Eskildsen-Larsen, et al. 2011. The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities. J. Interferon Cytokine Res. 31: 41–47
   PubMed Web of Science ®Google Scholar
• Hovanessian, A. G., R. E. Brown, and I. M. Kerr. 1977. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature. 268: 537–540
   PubMedGoogle Scholar
• Kristiansen, H., C. A. Scherer, M. McVean, et al. 2010. Extracellular 2′-5′ oligoadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity. J. Virol. 84: 11898–11904
   PubMedGoogle Scholar
• Marques, J., J. Anwar, S. Eskildsen-Larsen, et al. 2008. The p59 oligoadenylate synthetase-like protein possesses antiviral activity that requires the C-terminal ubiquitin-like domain. J. Gen. Virol. 89: 2767–2772
   PubMedGoogle Scholar
• Eskildsen, S., J. Justesen, M. H. Schierup, and R. Hartmann. 2003. Characterization of the 2′-5′-oligoadenylate synthetase ubiquitin-like family. Nucl. Acids Res. 31: 3166–3173
   PubMed Web of Science ®Google Scholar
• Hovnanian, A., D. Rebouillat, M. G. Mattei, et al. 1998. The human 2′,5′-oligoadenylate synthetase locus is composed of three distinct genes clustered on chromosome 12q24.2 encoding the 100-, 69-, and 40-kDa forms. Genomics. 52: 267–277
   PubMed Web of Science ®Google Scholar
• Witt, P. L., I. Marie, N. Robert, et al. 1993. Isoforms p69 and p100 of 2′,5′-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J. Interferon Res. 13: 17–23
   PubMedGoogle Scholar
• Melchjorsen, J., H. Kristiansen, R. Christiansen, et al. 2009. Differential regulation of the OASL and OAS1 genes in response to viral infections. J. Interferon Cytokine Res. 29: 199–207
   PubMed Web of Science ®Google Scholar
• Rebouillat, D., A. Hovnanian, G. David, et al. 2000. Characterization of the gene encoding the 100-kDa form of human 2′,5′ oligoadenylate synthetase. Genomics. 70: 232–240
   PubMed Web of Science ®Google Scholar
• Wang, Q., and G. Floyd-Smith. 1997. The p69/71 2-5A synthetase promoter contains multiple regulatory elements required for interferon-alpha-induced expression. DNA Cell. Biol. 16: 1385–1394
   PubMedGoogle Scholar
• Dan, M., D. Zheng, L. L. Field, and V. Bonnevie-Nielsen. 2012. Induction and activation of antiviral enzyme 2′,5′-oligoadenylate synthetase by in vitro transcribed insulin mRNA and other cellular RNAs. Mol. Biol. Rep. 39: 7813–7822
   PubMedGoogle Scholar
• Ghosh, A., S. N. Sarkar, T. M. Rowe, and G. C. Sen. 2001. A specific isozyme of 2′-5′ oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J. Biol. Chem. 276: 25447–25455
   PubMedGoogle Scholar
• Dugan, J. W., A. Albor, L. David, et al. 2009. Nucleotide oligomerization domain-2 interacts with 2′-5′-oligoadenylate synthetase type 2 and enhances RNase-L function in THP-1 cells. Mol. Immunol. 47: 560–566
   PubMedGoogle Scholar
• Lee, M. S., B. Kim, G. T. Oh, and Y. J. Kim. 2013. OASL1 inhibits translation of the type I interferon-regulating transcription factor IRF7. Nat. Immunol. 14: 346–355
   PubMed Web of Science ®Google Scholar
• Cagliani, R., M. Fumagalli, F. R. Guerini, et al. 2012. Identification of a new susceptibility variant for multiple sclerosis in OAS1 by population genetics analysis. Hum. Genet. 131: 87–97
   PubMedGoogle Scholar
• Ye, S., Q. Guo, J. P. Tang, et al. 2007. Could 2′5′-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients? A pilot study. Clin. Rheumatol. 26: 186–190
   PubMedGoogle Scholar
• Coelho, L. F., J. G. de Oliveira, D. B. de Oliveira, et al. 2007. Increased expression of 2′5′oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients. Arch. Dermatol. Res. 299: 259–262
   PubMedGoogle Scholar
• de Oliveira, D. B., G. M. Almeida, A. C. Guedes, et al. 2011. Basal activation of type I interferons (Alpha2 and Beta) and 2′5′OAS genes: insights into differential expression profiles of interferon system components in systemic sclerosis. Int. J. Rheumatol. 2011: 275617
   PubMedGoogle Scholar
• Chizzolini, C., N. C. Brembilla, E. Montanari, and M. E. Truchetet. 2011. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun. Rev. 10: 276–281
   PubMed Web of Science ®Google Scholar
• Denton, C. P., and C. M. Black. 2004. Scleroderma – clinical and pathological advances. Best Pract. Res. Clin. Rheumatol. 18: 271–290
   PubMed Web of Science ®Google Scholar
• Abraham, D. J., and J. Varga. 2005. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 26: 587–595
   PubMed Web of Science ®Google Scholar
• Hikami, K., Y. Ehara, M. Hasegawa, et al. 2008. Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem. Biophys. Res. Commun. 373: 403–407
   PubMed Web of Science ®Google Scholar
• Assassi, S., M. D. Mayes, F. C. Arnett, et al. 2010. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 62: 589–598
   PubMedGoogle Scholar
• Molteni, M., S. Della Bella, B. Mascagni, et al. 1999. Increased interferon-gamma (IFN-γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin. Exp. Immunol. 116: 164–168
   PubMedGoogle Scholar
• Valentini, G., A. Baroni, K. Esposito, et al. 2001. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J. Clin. Immunol. 21: 210–217
   PubMed Web of Science ®Google Scholar
• Coelho, L. F., J. G. de Oliveira, and E. G. Kroon. 2008. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma? Immunol. Lett. 118: 110–115
   PubMed Web of Science ®Google Scholar
• Jaitin, D. A., L. C. Roisman, E. Jaks, et al. 2006. Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol. Cell. Biol. 26: 1888–1897
   PubMed Web of Science ®Google Scholar
• Francois-Newton, V., G. Magno de Freitas Almeida, B. Payelle-Brogard, et al. 2011. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One. 6: e22200
   PubMed Web of Science ®Google Scholar